Aesica comments on the General Drug User Fee Amendments (GDUFA)

Aesica comments robustly in the thought leadership feature article, published in the March edition of Contract Pharma Magazine.

On the one hand, the company predicts the positive impact of driving up quality standards through increased inspections, whilst making a reasoned case for looking again at the blanket cost for all companies that manufacture generic drugs. These are specifically the high quality manufacturers, which threaten to drive up drug prices.

Read the full article

  • News
  • Case Studies
  • Pages
  • Blogs
  • Locations
  • Experts